Dr. Fazal Adnan
is working as
Associate Professor
in the
Atta-Ur-Rahman School of Applied Biosciences
. Dr. Fazal Adnan
has a PhD in
Bacterial Gene Expression/Regulation
. Dr. Fazal Adnan
has published
53
research articles & conference papers having a citation count of
654
, carried out
7
projects and filed
1
intellectual property.
Investigating resistome, virulence and zoonotic potential of Mammary Pathogenic E. coli (MPEC) strains isolated from mastitic dairy and Machine Learning approach for risk factors assessment2023
Funding Agency: The swiss global network for education, research and innovation
CRISPR-CAS3 Mediated Whole Genome Excision of the Avian Pathogenic E. coli (APEC); Designing Precision Antibacterial against Colibacillosis in Poultry2019
Journal: Plos ONE, Volume 8(11), Article Number e79520
Impact Factor: 3.534Citations: 23Quartile: 1
High Occurrence of Multidrug-Resistant Escherichia coli Strains in Bovine Fecal Samples from Healthy Cows Serves as Rich Reservoir for AMR Transmission2022
Journal: Nano-Structures and Nano-Objects, Volume:40, Article Number 101415
Impact Factor: N/ACitations: 3Quartile: N/A
Imidazolium, pyridinium and pyrazinium based ionic liquids with octyl side chains as potential antibacterial agents against multidrug resistant uropathogenic E. coli2024
SI
Sidrah Hafeez
ZA
Zamar rasool Awan
SA
Samia Hafeez
(Pakistan Institute of Medical Sciences)
Journal: Desalination and Water Treatment , Vol.171, Pages 62–66
Impact Factor: 0.854Citations: 3Quartile: 4
Mycorrhizosphere bacteria inhibit greenhouse gas emissions from microplastics contaminated soil by regulating soil enzyme activities and microbial community structure2024
Synthesis, evaluation, and in silico studies of imidazolium and pyridinium-based ionic liquids with Dioctyl succinamic acid anion for enhanced antibacterial applications2024
Journal: Saudi Journal of Biological Sciences, Volume 31, Issue 1, Article Number 103884
Impact Factor: 4.400Citations: 0Quartile: 1
Lactobacillus reuteri and Enterococcus faecium from Poultry Gut Reduce Mucin Adhesion and Biofilm Formation of Cephalosporin and Fluoroquinolone-Resistant Salmonella enterica2021
Malik Nawaz Shuja
(Kohat University of Science and Technology)
HA
Hazir Rahman
(Abdul Wali Khan University)
Journal: Infection, Genetics and Evolution, Volume 93, Article Number 104922
Impact Factor: 3.342Citations: 1Quartile: 3
High resistance of fluoroquinolone and macrolide reported in avian pathogenic Escherichia coli isolates from the humid subtropical regions of Pakistan2023
Muhammad Qasim
(Kohat University of Science and Technology)
Journal: Journal of Exploratory Research in Pharmacology , Volume 6(2), Pages 44-52
Impact Factor: N/ACitations: 0Quartile: N/A
Enrichment of the hydrogenotrophic methanogens for, in-situ biogas up-gradation by recirculation of gases and supply of hydrogen in methanogenic reactor2022
AL
Alam Khan
(Quaid-i-Azam University)
SE
Sedrah Akbar
(Quaid-i-Azam University)
VA
Valentine Okonkwo
(University of Glasgow)
CI
Cindy Smith
(National University of Ireland Galway)
M. Umar Khayam
(Sarhad University of Science and Information Technology)
M
Mohammad Amjad Kamal
(King Abdulaziz University)
SH
Shafiq Ahmad
(Khyber Medical University)
AH
Ahmed Jawad
(Khyber Medical University)
IS
Ishaq N. Khan
(King Abdulaziz University)
Journal: Current Drug Metabolism , Volume 19(11), Pages 902-909
Impact Factor: 2.277Citations: 18Quartile: 3
Assessment of the risk for human health of Enterovirus and Hepatitis A virus in clinical and water sources from three metropolitan cities of Pakistan2018
Conference: 4th International Conference on emerging trends in Bioinformatics and Biosciences (ICETBB-2022)
Citations: N/A
Understanding the Diversity of Antibiotic Resistance and Emergence of Hybrid e. Coli Strains; a Cross-Sectional Study of Mammary Pathogenic e. Coli (MPEC) Isolates from Mastitic Milk
Book: Book on Bioremediation and Biotechnology (Chapter 14, Pages 293-303) Citations: 4
0
Copyrights
1
Patents
0
Industrial Designs
0
Trademarks
A composition for construction of dual expression construct "Anti-HBV Cargo" designed as a CRISPR/Cas9 mediated therapeutic strategy to counter HBV persistence"
2023
